Role of the clinical pharmacy technician in a Veterans Affairs pain management clinic

The scope of practice for clinical pharmacy specialists within the Veterans Health Administration (VHA) includes independent management of medication therapy. The evolving role of the clinical pharmacist influences the role of the pharmacy technician. VHA recognizes the need for clinical pharmacy technicians and provides guidance on potential activities for clinical pharmacy technicians.1

The VHA Opioid Safety Initiative launched in October 2013 to improve pain management outcomes and address the risks of long-term opioid therapy. In response, our Veterans Integrated Service Network developed a pain clinical dashboard to facilitate the tracking of high-dose long-term opioid therapy, naloxone distribution, informed consent for long-term opioid therapy, prescription drug monitoring program (PDMP) documentation, and urine drug screen (UDS) monitoring. Furthermore, VHA emphasizes an interdisciplinary patient care model for pain management.2 At VA Northern California Health Care System, under the supervision of the pain clinical pharmacy specialists, the pain clinical pharmacy technician (PCPT) position was established to support the provision of safe and optimal long-term opioid therapy.

The PCPT accesses the pain clinical dashboard for patients prescribed long-term opioid therapy. Patients with upcoming appointments are identified and those requiring action are alerted to the provider. In addition, results of PDMP queries are documented, allowing the provider to access information ahead of the appointment.

As a delegate under the pain clinical pharmacy specialist, the PCPT makes inquiries in the PDMP system and enters the results in the patient’s electronic health record, documenting non-VHA controlled medications for provider review. In addition, the PCPT assists providers with PDMP queries as requested to facilitate timely decisions about initiating opioid therapy. Providers can ensure there are no duplicate controlled medications or potentially dangerous drug–drug interactions. California Senate Bill 482,3 the Centers for Disease Control and Prevention guideline,4 and VHA Directive 13065 provide recommendations for the frequency of PDMP database queries. Adherence to PDMP query recommendations will affect workload; thus, assistance from PCPTs could become increasingly important.

The PCPT assists with obtaining a UDS for patients prescribed long-term opioid therapy. A laboratory order is placed by the PCPT for clinician signature, and laboratory reminder letters and telephone calls are directed to patients for completion. Both the ordering individual and the signing clinician receive alerts regarding UDS results. UDS results are screened by the PCPT for illicit drug use and appropriateness based on the current medication regimen. The PCPT also assists with initiating further action, such as a repeat UDS or confirmatory testing.

The PCPT performs chart reviews to examine intervals for refill and renewal requests for medication adherence, historical UDS and PDMP results for possible aberrant behaviors, and unfulfilled clinic appointments or laboratory tests for continuity of care.

When consultations for the pain clinical pharmacy specialist are ordered, the PCPT evaluates information to determine referral eligibility. Patients taking more than 90 morphine milligram equivalents daily are at highest risk for opioid-related harm and are prioritized. Referred patients are then contacted by the PCPT to schedule an appointment with the pain clinical pharmacy specialist.

The PCPT actively participates in teaching pharmacy students who are completing introductory pharmacy practice experiences in population management for patients prescribed long-term opioid therapy. The PCPT conducts in-classroom training at the University of the Pacific on navigating the electronic health record, including the laboratory, pharmacy, and patient demographic sections. In addition, strategies are provided to conduct accurate

The Letters column is a forum for rapid exchange of ideas among readers of AJHP. Liberal criteria are applied in the review of submissions to encourage contributions to this column.

The Letters column includes the following types of contributions: (1) comments, addenda, and minor updates on previously published work, (2) alerts on potential problems in practice, (3) observations or comments on trends in drug use, (4) opinions on apparent trends or controversies in drug therapy or clinical research, (5) opinions on public health issues of interest to pharmacists in health systems, (6) comments on ASHP activities, and (7) human interest items about life as a pharmacist. Reports of adverse drug reactions must present a reasonably clear description of causality.

Short papers on practice innovations and other original work are included in the Notes section rather than in Letters. Letters commenting on an AJHP article must be received within 3 months of the article’s publication.

Letters should be submitted electronically through http://ajhp.msubmit.net. The following conditions must be adhered to: (1) the body of the letter must be no longer than 2 typewritten pages, (2) the use of references and tables should be minimized, and (3) the entire letter (including references, tables, and authors’ names) must be typed double-spaced. After acceptance of a letter, the authors are required to sign an exclusive publication statement and a copyright transferal form. All letters are subject to revision by the editors.
Coenzyme Q10 for statin-associated myalgia

We read with great interest the article by Tan and Barry about coenzyme Q10 supplementation in the management of statin-associated myalgia (SAM) and believe that the authors omitted clinically relevant information. We use coenzyme Q10 supplementation in our practice and believe it plays a role in a subset of patients experiencing SAM.

In its pure form, coenzyme Q10, or ubiquinone, is a water-insoluble powder and has incomplete lipid solubility, resulting in poor absorption and limited oral bioavailability. However, there are pharmacokinetic data demonstrating that the reduced form of coenzyme Q10, or ubiquinol, has greater bioavailability and produces higher plasma concentrations when consumed orally, compared with ubiquinone.

Therefore, the ubiquinol formulation may be more likely to provide benefit in certain patients with SAM. Although Tan and Barry briefly discussed coenzyme Q10 product variability, they did not mention ubiquinol specifically or list it among their search terms.


Jamie Lynn Kennison, CPhT
Primary Care Service
Sacramento VA Medical Center
Mather, CA

Sian Carr-Lopez, Pharm.D., FASHP
Primary Care Service
VA Northern California Health Care System
Mather, CA
sian.carr-lopez@va.gov

Tracey Le, Pharm.D.
Primary Care Service
Sacramento VA Medical Center
Mather, CA

Jeremiah McKelvey, Pharm.D.
Pharmacy Service
VA Northern California Health Care System
Martinez, CA

The authors have declared no potential conflicts of interest.
Keywords: clinical pharmacy technician, opioid safety, pain management

Copyright © 2018, American Society of Health-System Pharmacists, Inc. All rights reserved. 1079-2082/18/0102-0013.
DOI 10.2146/ajhp170401